The local medical sector is excited with the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor showing remarkable results in clinical trials for addressing obesity. This treatment promises https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/